Advertisement

Introduction to Cannabis Use Disorders

  • Ivan D. MontoyaEmail author
  • Susan R. B. Weiss
Chapter

Abstract

Cannabis is a natural product that, when used chronically, has been associated with the development of cannabis use disorder. This disorder, as described in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) of the American Psychiatric Association (2013. Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC), is clinically characterized by the inability to stop using cannabis despite psychosocial/medical problems, the presence of craving, the need to use larger amounts to obtain the same effect (tolerance), and/or the onset of symptoms when its use is stopped (withdrawal). The current increase in the frequency of cannabis use, the availability and use of cannabis products with high concentration of the psychoactive ingredient tetrahydrocannabinol (THC), and the presence in the markets of highly potent synthetic cannabinoids may result in an increased risk of CUD. Recent studies have provided a wealth of information about the endocannabinoid system, the effects of cannabinoids, and the brain mechanisms of CUD. These new discoveries are allowing the identification of novel pharmacological targets and medications that may affect the endocannabinoid system and may be useful for the treatment of CUD and other medical conditions. The purpose of this book is to provide an overview of the epidemiology, neurobiological basis, developmental aspects, and clinical characteristics of CUD, including its pharmacological and non-pharmacological therapeutic approaches.

Keywords

Cannabis Cannabinoids Marijuana Epidemiology Treatment Endocannabinoids 

References

  1. 1.
    Drug Enforcement Administration. Drug schedules. 2018. https://www.dea.gov/druginfo/ds.shtml [On-line]. Available: https://www.dea.gov/druginfo/ds.shtml.
  2. 2.
    Compton WM, Baler R. The epidemiology of DSM-5 Cannabis use disorders among U.S. adults: science to inform clinicians working in a shifting social landscape. Am J Psychiatry. 2016;173:551–3.CrossRefGoogle Scholar
  3. 3.
    Mauro CM, Newswanger P, Santaella-Tenorio J, et al. Prev Sci. 2017; https://doi.org/10.1007/s11121-017-0848-3.
  4. 4.
    Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219–27.CrossRefGoogle Scholar
  5. 5.
    Substance Abuse and Mental Health Services Administration Reports and detailed tables from the 2016 National Survey on Drug Use and Health (NSDUH). 2018. https://www.samhsa.gov/samhsa-data-outcomes-quality/major-data-collections/reports-detailed-tables-2016-NSDUH [On-line]. Available: https://www.samhsa.gov/samhsa-data-outcomes-quality/major-data-collections/reports-detailed-tables-2016-NSDUH.
  6. 6.
    Miech R, Johnston L, O’Malley PM. Prevalence and attitudes regarding marijuana use among adolescents over the past decade. Pediatrics. 2017;140:e20170982.CrossRefGoogle Scholar
  7. 7.
    Compton WM, Volkow ND, Lopez MF. Medical Marijuana Laws and Cannabis use: intersections of health and policy. JAMA Psychiat. 2017;74:559–60.CrossRefGoogle Scholar
  8. 8.
    Han B, Compton WM, Blanco C, Jones CM. Trends in and correlates of medical marijuana use among adults in the United States. Drug Alcohol Depend. 2018;186:120–9.CrossRefGoogle Scholar
  9. 9.
    Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017;104:13–23.CrossRefGoogle Scholar
  10. 10.
    Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiat. 2015;72:1235–42.CrossRefGoogle Scholar
  11. 11.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  12. 12.
    Gates P, Albertella L, Copeland J. Cannabis withdrawal and sleep: a systematic review of human studies. Subst Abus. 2016a;37:255–69.CrossRefGoogle Scholar
  13. 13.
    Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: a review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4:75–81.CrossRefGoogle Scholar
  14. 14.
    Mechoulam R, Ben SS, Hanus L, Fride E, Vogel Z, Bayewitch M, et al. Endogenous cannabinoid ligands–chemical and biological studies. J Lipid Mediat Cell Signal. 1996;14:45–9.CrossRefGoogle Scholar
  15. 15.
    Mechoulam R, Gaoni Y. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron. 1965;21:1223–9.CrossRefGoogle Scholar
  16. 16.
    Mechoulam R. The endocannabinoid system: a look back and ahead. Handb Exp Pharmacol. 2015;231:vii–x.PubMedGoogle Scholar
  17. 17.
    Ton NCJM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, et al. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res. 1988;451:59–68.CrossRefGoogle Scholar
  18. 18.
    Volkow ND, Hampson AJ, Baler RD. Don’t worry, be happy: endocannabinoids and Cannabis at the intersection of stress and reward. Annu Rev Pharmacol Toxicol. 2017;57:285–308.CrossRefGoogle Scholar
  19. 19.
    Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology. 2003;169:135–40.CrossRefGoogle Scholar
  20. 20.
    Maldonado R, Rodriguez de FF. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci. 2002;22:3326–31.CrossRefGoogle Scholar
  21. 21.
    Panlilio LV, Justinova Z. Preclinical studies of cannabinoid reward, treatments for Cannabis use disorder, and addiction-related effects of cannabinoid exposure. Neuropsychopharmacology. 2018;43:116–41.CrossRefGoogle Scholar
  22. 22.
    Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms–a review of recent preclinical data. Psychopharmacology. 2003;169:115–34.CrossRefGoogle Scholar
  23. 23.
    Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the field: death following ingestion of an edible Marijuana product–Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64:771–2.CrossRefGoogle Scholar
  24. 24.
    Onders B, Casavant MJ, Spiller HA, Chounthirath T, Smith GA. Marijuana exposure among children younger than six years in the United States. Clin Pediatr (Phila). 2016;55:428–36.CrossRefGoogle Scholar
  25. 25.
    Smith R, Hall KE, Etkind P, Van DM. Current marijuana use by industry and occupation – Colorado, 2014-2015. MMWR Morb Mortal Wkly Rep. 2018;67:409–13.CrossRefGoogle Scholar
  26. 26.
    Montoya ID, McCann DJ. Drugs of abuse: management of intoxication and antidotes. EXS. 2010;100:519–41.PubMedGoogle Scholar
  27. 27.
    Zanda MT, Fattore L. Old and new synthetic cannabinoids: lessons from animal models. Drug Metab Rev. 2018;50:54–64.CrossRefGoogle Scholar
  28. 28.
    Large M, Di FM, Murray R. Cannabis: debated schizophrenia link. Nature. 2015;527:305.CrossRefGoogle Scholar
  29. 29.
    Mane A, Fernandez-Exposito M, Berge D, Gomez-Perez L, Sabate A, Toll A, et al. Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Psychiatry Res. 2015;229:70–4.CrossRefGoogle Scholar
  30. 30.
    Negrete JC, Knapp WP. The effects of cannabis use on the clinical condition of schizophrenics. NIDA Res Monogr. 1986;67:321–7.PubMedGoogle Scholar
  31. 31.
    Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99:425–30.CrossRefGoogle Scholar
  32. 32.
    Jett J, Stone E, Warren G, Cummings KM. Cannabis use, lung cancer, and related issues. J Thorac Oncol. 2018;13:480–7.CrossRefGoogle Scholar
  33. 33.
    Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the current knowledge about the cardiovascular risk for users of Cannabis-based products? A systematic review. Curr Atheroscler Rep. 2017;19:26.CrossRefGoogle Scholar
  34. 34.
    Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of Cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73:292–7.CrossRefGoogle Scholar
  35. 35.
    American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation. Obstet Gynecol. 2015;126:234–8.CrossRefGoogle Scholar
  36. 36.
    Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, Koroshetz WJ, et al. The conception of the ABCD study: from substance use to a broad NIH collaboration. Dev Cogn Neurosci. 2018;32:4–7.CrossRefGoogle Scholar
  37. 37.
    Gates PJ, Sabioni P, Copeland J, Le FB, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev. 2016b:CD005336.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Therapeutics and Medical ConsequencesNational Institute on Drug AbuseBethesdaUSA
  2. 2.Division of Extramural ResearchNational Institute on Drug AbuseBethesdaUSA

Personalised recommendations